Biotechnology
Sort by: Featured Most recent Most read Most commented
75 results total, viewing 11 - 20
IlluminOss taps Kuyper as president and CEO
IlluminOss Medical Inc. has named Dirk M. Kuyper its new president and CEO effective Monday. Kuyper is taking over for Scott Rader, whose position with the company ended in late October, the company announced Tuesday. more
| 4/9/13
Amgen tops analyst estimates as profit benefits from tax credit
Amgen Inc., which has a production facility in West Greenwich, reported first-quarter profit that beat analyst estimates because of a research tax credit. more
Covidien’s profits drop in 2Q as sales rise 5%
Medical technology maker Covidien Plc reported second-quarter earnings of $439 million, or 92 cents per diluted share, an 11.7 percent drop from the $497 million, or $1.02 per diluted share, it reported during the second quarter of 2012. more
| 4/26/13
Amgen drugs may boost survival after a nuclear attack
Amgen Inc.’s Neulasta and Neupogen and a similar blood-boosting drug from Teva Pharmaceutical Industries Ltd. may help people survive after a nuclear attack, U.S. regulators said. more
Jewelry designer, tennis online booking service, 3D printing marketplace win Business Plan
The 2013 edition of the Rhode Island Business Plan Competition announced its winners Tuesday afternoon at The Garage, the Greater Providence Chamber of Commerce’s exposition dedicated to identifying and inspiring high-growth companies in the Ocean State. more
| 5/14/13
Mass. biotech firms look to prepare vets for openings to come
A group of human resource executives from five Massachusetts biotechnology companies gathered Tuesday to brainstorm how to better prepare military veterans for jobs in the sector, according to the Boston Business Journal. more
| 5/15/13
Covidien approves separation of pharmaceuticals arm
Medical technology maker Covidien PLC’s board of directors has approved the separation of its Mallinckrodt pharmaceuticals business from the rest of Covidien, the company announced Friday. more
| 5/24/13
Amgen gets high court review of class-action stock fraud suit
The U.S. Supreme Court will decide whether investors must prove that misinformation from Amgen Inc. propped up its stock price before they can pursue a class-action stock-fraud suit against the world’s largest biotechnology company. more
Innovation, diversity is the best medicine for Amgen
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. more
By Richard Asinof
Contributing Writer | 6/25/12
Covidien completes Oridion acquisition
Medical device maker Covidien PLC has completed its acquisition of Oridion Systems Ltd., the company announced Tuesday. more
| 6/27/12
« Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 … 8 | Next »
Calendar
PBN Hosted
Events

Celebrate RI's many exceptional women at PBN's Business Women Awards luncheon May 30th at the Providence Marriott. Reserve your seat today!
Advertisement
National
Local
Latest News